Novel Therapeutics from Modern Biotechnology: From Laboratory to Human Testing

Product Description
This volume addresses the particular problems associated with several classes of biotechnology products, and at the same time demonstrates that the principles are the same as in the development of small new chemical entities. The first chapter addresses FDA regulatory expectations for biotech products. The next several chapters discuss general issues common to each class of biotech drug such as proteins, peptides, and nucleic acids. The balance of the chapters deal with specific biotech drugs that have successfully made it into clinical trials. The reviews are written by renowned experts in their fields.

Novel Therapeutics from Modern Biotechnology: From Laboratory to Human Testing

Affymax And Takeda Report Phase 2 Analyses Of Hematide™/peginesatide In Hemodialysis Patients

Affymax And Takeda Report Phase 2 Analyses Of Hematide™/peginesatide In Hemodialysis Patients
Affymax, Inc. (Nasdaq: AFFY) and Takeda Global Research & Development Center, Inc., U.S., today announced data from several post hoc analyses of Phase 2 clinical trials that evaluated Hematide/peginesatide in dialysis patients with anemia in chronic kidney disease (CKD). The data provide hypotheses for further investigation of this agent in anemia management in this patient population. The …

Read more on Medical News Today

Affymax and Takeda Report Phase 2 Analyses of Hematide/peginesatide in Hemodialysis Patients

Affymax and Takeda Report Phase 2 Analyses of Hematide/peginesatide in Hemodialysis Patients
ORLANDO, Fla.—-Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced data from several post hoc analyses of Phase 2 clinical trials that evaluated Hematide/peginesatide in dialysis patients with anemia in chronic kidney disease .

Read more on Business Wire via Yahoo! Finance

The Handbook of Biomarkers

Product Description

Of the thousands of biomarkers that are currently being discovered, relatively few are being validated for further applications, and the potential of a biomarker can be quite difficult to evaluate. To aid in this imperative research, Dr. Kewal K. Jain’s Handbook of Biomarkers thoroughly describes many different types of biomarkers and their discovery using various “-omics” technologies, such as proteomics and metabolomics, along with the background information needed for the evaluation of biomarkers as well as the essential procedures for their validation and use in clinical trials. With biomarkers described first according to technologies and then according to various diseases, this detailed book features the key correlations between diseases and classifications of biomarkers, which provides the reader with a guide to sort out current and future biomarkers.

Comprehensive and cutting-edge, The Handbook of Biomarkers serves as a vital guide to furthering our understanding of biomarkers, which, by facilitating the combination of therapeutics with diagnostics, promise to play an important role in the development of personalized medicine, one of the most important emerging trends in healthcare today.

The Handbook of Biomarkers

Biotech Stocks on the Move

* Merriman Curhan Ford 5th Annual Investor Summit * Curis cancer drug in clinical trials * genvec cancer drug enters Phase III * medicinova discusses early test for asthma and MS drugs

« Previous Page — Next Page »